Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at April 30, 2026, the issued share capital of HUTCHMED consist
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 9, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2025 Annual Report, together with the Notice of Annual General Meeting and the Form
Hong Kong, Shanghai & Florham Park, NJ — Friday, February 6, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Prof Shun Lu, Pr
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 29, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announces the following blocklisting six monthly return:
1.
Name
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 21, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on